Relationship between isotope, prostate volume and urinary morbidity following prostate brachytherapy

被引:0
|
作者
Butler, W [1 ]
Niehaus, A [1 ]
Merrick, G [1 ]
Allen, Z [1 ]
Galbreath, R [1 ]
Adamovich, E [1 ]
机构
[1] Wheeling Hosp, Wheeling, WV USA
关键词
D O I
10.1118/1.1997722
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To evaluate the influence of isotope and prostate size on International Prostate Symptom Score (IPSS) normalization, catheter dependency and the need for surgical intervention following permanent prostate brachytherapy. Method and Materials: 976 consecutive patients underwent permanent brachytherapy for clinical stage T1b‐T3a prostate cancer. Of these, 789 were implanted with Pd‐103 and 187 with I‐125. Patients were stratified into size cohorts ⩽ 25.0 cm3, 25–35 cm3, 35–45 cm3, and > 45.0 cm3. 418 received androgen deprivation therapy (ADT). 486 received supplemental external beam radiation therapy (XRT). In all patients, an α‐blocker was initiated prior to implantation and continued until the IPSS returned to baseline. The median number of IPSS determinations per patient was 21. Clinical, treatment and dosimetric parameters evaluated included patient age, pretreatment PSA, Gleason score, clinical T‐stage, percent positive biopsies, preimplant IPSS, ultrasound volume, planning volume, isotope, V100/150/200, D90, urethral dose, supplemental XRT, ADT, and the duration of ADT (⩽ 6 months versus > 6 months). Results: For both isotopes and all size cohorts, IPSS peaked 1 month following implantation and returned to baseline at a mean of 1.9 months. Stratification of prostate size cohorts by isotope resulted in no significant differences in prolonged catheter dependency, IPSS resolution or postimplant surgical intervention. In Cox regression analysis, IPSS normalization was best predicted by preimplant IPSS, XRT and any need for a catheter following brachytherapy. Catheter dependency correlated with prostate volume, while the need for surgical intervention was related to catheter dependency, maximum urethral dose, ADT and maximum IPSS increase. Conclusion: When stratified by prostate size, the choice of isotope did not impact IPSS resolution, catheter dependency or the need for postbrachytherapy surgical intervention. While prostate size did predict for short‐term (< 5 day) catheter dependency, it did not influence IPSS resolution or the need for surgical intervention. © 2005, American Association of Physicists in Medicine. All rights reserved.
引用
收藏
页码:1961 / 1961
页数:1
相关论文
共 50 条
  • [31] The relationship of International Prostate Symptom score with urinary flow studies, and catheterization rates following iodine 125 prostate brachytherapy
    Martens, CG
    Webster, D
    Pond, G
    Crook, J
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S312 - S312
  • [32] Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following iodine 125 prostate brachytherapy
    Martens, C
    Webster, D
    Pond, G
    Crook, J
    RADIOTHERAPY AND ONCOLOGY, 2005, 76 : S59 - S60
  • [33] PREDICTORS OF URINARY MORBIDITY IN Cs-131 PROSTATE BRACHYTHERAPY IMPLANTS
    Smith, Ryan P.
    Jones, Heather A.
    Beriwal, Sushil
    Gokhale, Abhay
    Benoit, Ronald
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (03): : 745 - 750
  • [34] The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry
    Neill, Mischel
    Studer, Gabrielle
    Le, Lisa
    McLean, Michael
    Yeung, Ivan
    Pond, Greg
    Crook, Juanita A.
    BRACHYTHERAPY, 2007, 6 (03) : 173 - 179
  • [35] The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry
    Crook, J.
    Neill, M.
    Le, L.
    Studer, G.
    McLean, M.
    Pond, G.
    RADIOTHERAPY AND ONCOLOGY, 2007, 84 : S6 - S7
  • [36] Optimal Equations for Describing the Relationship Between Prostate Volume, Number of Sources, and Total Activity in Permanent Prostate Brachytherapy
    Aronowitz, Jesse N.
    Michalski, Jeff M.
    Merrick, Gregory S.
    Sylvester, John E.
    Crook, Juanita M.
    Butler, Wayne M.
    Mawson, Christie
    Pratt, David
    Naidoo, Devi
    Karolczuk, Kathryn
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (02): : 164 - 167
  • [37] Characteristics of Patients with Long-term Urinary Morbidity following Cs-131 Prostate Brachytherapy
    Smith, R. P.
    Jones, H. A.
    Beriwal, S.
    Gokhale, A.
    Benoit, R. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S351 - S351
  • [38] The impact of acute urinary morbidity on late urinary function after permanent prostate brachytherapy
    Bittner, Nathan
    Merrick, Gregory S.
    Wallner, Kent E.
    Lief, Jonathan H.
    Butler, Wayne M.
    Galbreath, Robert W.
    BRACHYTHERAPY, 2007, 6 (04) : 258 - 266
  • [39] Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy
    Gutman, S
    Merrick, GS
    Butler, WM
    Wallner, KE
    Allen, Z
    Galbreath, RW
    Adamovich, E
    BJU INTERNATIONAL, 2006, 97 (01) : 62 - 68
  • [40] Urinary morbidity in patients with high ipss or larger prostate glands submitted to iodine 125 prostate brachytherapy
    Pinheiro, L.
    Varregoso, J.
    Rosario, V.
    Ugidos, J.
    Teixeira, N.
    Cunha, G.
    Ferreira, A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 227 - 227